List view / Grid view
The hit-to-lead journey can be a long endeavour, with many failures along the way. Nikki Withers spoke with DNDi ’s Discovery Director Dr Charles Mowbray to hear how the organisation is working to identify new leads with activity in animal models of neglected tropical diseases and the potential for further…
New research has categorised hundreds of cancers based on their common protein mutations, highlighting cell components and tumour microenvironments as possible new therapy targets.
A new study has presented a potential strategy for a universal human cancer vaccine. This article delves into the researchers’ findings, exploring their methodologies and results.
A study has demonstrated that dendritic cells play a key role in inflammation and how TNF inhibitors can prevent them from fighting infections.
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
Researchers have used ghost imaging to enhance the imaging speed of nanoscopy, which could make it possible to capture processes in living cells at speeds not previously possible.
Scientists have evaluated mouse models used for developing treatments for mood disorders associated with Huntington's disease and have recommended which have greater potential for success.
A study in mice has shown that immunisation against bacterial flagellin could lead to protection from chronic inflammatory diseases.
VTP50469, a new targeted therapy for MLL-rearranged leukaemia, shows greater efficacy and fewer side-effects in mice, according to new research.
Endogenous human antibodies can be used to build and dismantle 2D and 3D DNA nanostructures, finds new research.
A study has demonstrated the success of changing the genome of mice, regulating the production of the C11orf46 gene.
Researchers have found that damage to mitochondria due to sepsis may be the cause of muscle weakness in mice.
Researchers have found that a type of T cell, called a Tr1 cell, could work as a therapeutic strategy for inflammatory bowel disease in children.
